Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3. Selvaggi, G., Wu, Y., Wang, Z., Wu, G., Poddubskaya, E., Reck, M., Mok, T., Chiappori, A., Lee, D. H., Breder, V., Orlov, S., Cicin, I., Cheng, Y., Liu, Y., Fan, Y., Zhou, J., Liang, C., Mao, L., Horn, L., Wakelee, H. A. ELSEVIER SCIENCE INC. 2021: S232–S233

View details for Web of Science ID 000631349600306